AstraZeneca To Acquire Fusion For Cancer Treatment
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates for cancer treatment AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients […]
AstraZeneca To Acquire Fusion For Cancer Treatment Read More »